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The attitude of women toward current and future
possibilities of diagnostic testing in maternal blood
using fetal DNA
Loes Kooij1*, Tjeerd Tymstra1 and Paul van den Berg2
1Department of Health Sciences, University Medical Centre Groningen, The Netherlands
2Department of Obstetrics and Gynecology, University Medical Centre, Groningen, The Netherlands
Objective To determine the opinions of women about the new developments in the field of noninvasive
prenatal diagnosis (NIPD).
Method Prospective study using questionnaires in two groups of women: women visiting the University
Medical Centre Groningen and the Martini Hospital Groningen for the routine fetal anomaly ultrasound scan
at 20 weeks’ gestation and female medical master students.
Results Both groups consider NIPD an important asset in the reliable diagnosis of fetal aneuploidy and
gender-determined genetic disorders, with the exception of disorders manifesting themselves later in life.
There is a negative response as to its application for family balancing. Eighty-two percent of the pregnant
women and 79% of the medical students responded positively to the question whether they consider NIPD an
important asset in prenatal care. The statement that it is an asset because it enables pregnant women to bear
an ‘optimal child’ is strongly rejected by both groups.
Conclusions NIPD paves the way for screening on a large scale. Our survey shows that women feel positive
about these new possibilities, but find it hard to fully realize the consequences and new choices they will be
confronted with. Copyright  2009 John Wiley & Sons, Ltd.
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INTRODUCTION
There are several methods for the detection of aneu-
ploidy in the fetus during pregnancy. Invasive proce-
dures such as amniocentesis and chorionic villus sam-
pling have been available since the 1970s. These tech-
niques are considered to be highly accurate but involve
a 0.5–2% risk of fetal loss. For that reason they are
mainly recommended to women with a greater risk for
having a pregnancy affected by Down syndrome. The
chance of a miscarriage is absent with the noninvasive
risk-assessment tests that have been developed in the last
two decades. They do not result in certainty, however,
but only in an individual risk assessment. At present the
test of maternal serum screening at 9 to 14 weeks’ gesta-
tion, in combination with nuchal translucency screening
between 11 and 14 weeks and maternal age, renders up
to a 90% accurate assessment of Down syndrome, with
a 5% false-positive rate (Spencer et al., 2003).
A new development is the possibility to isolate fetal
nucleic acids from maternal blood. It has been known
since 1997 that during pregnancy fetal DNA is present
in a pregnant woman’s blood (Lo et al., 1997). Recently
Lo showed that fetal mRNA transcripts can be used to
diagnose fetal aneuploidie (Lo et al., 2007). Currently
researchers worldwide are trying to develop techniques
*Correspondence to: Loes Kooij, Department of Health Sciences,
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that are to result in accurate testing for fetal aneuploidie
(Dhallan et al., 2007). It is quite possible that these tests
can already be applied in the first trimester of pregnancy.
By means of this new technology fetal screening for
Down syndrome will probably become available on a
large scale in the next decade, just as a routine screening
service. The test is relatively simple—a blood sample
of the pregnant woman will do—and the diagnose can
be given with a high certainty in the first trimester of
pregnancy (Dhallan et al., 2007).
Not only does the test offer new possibilities for the
detection of Down syndrome and other chromosomal
defects but it also indicates gender-related disorders.
Early fetal gender determination by means of noninva-
sive prenatal diagnosis (NIPD) is already being practiced
clinically. Prenatal applications have been laid down
for myotone dystrophy (Amicucci et al., 2000), cystic
fibrosis (Gonzales-Gonzales et al., 2002) and Hunting-
ton disease (Gonzales-Gonzales et al., 2003). Also in
case of congenital disorders occurring later in life, e.g.
breast cancer, early determination of gender could be
important. Additionally there is the possibility of deter-
mination of gender for nonmedical reasons, although this
is not generally accepted. The number of congenital dis-
orders that can be detected via NIPD will significantly
increase in the future. The application of these diagnostic
tools is therefore expected to become ever more popular.
The question remains what women’s opinions are as to
this development and its applications. How do they feel
about the existing possibilities and new developments in
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the field of prenatal diagnostics and screening? What do
they consider positive and where do they draw a line?
To find out we have taken a survey of women’s attitudes
toward current and future testing possibilities.
MATERIALS AND METHODS
To procure the information a questionnaire was submit-
ted to two groups of respondents: pregnant women and
women for whom the wish to have children is not (yet)
an issue at present. For the first group, women were
approached who made use of the routine fetal anomaly
ultrasound scan at 20 weeks’ gestation at the University
Medical Centre Groningen and the Martini Hospital in
Groningen. Only women with a negative scan (low-risk
women) were given the questionnaire with the request
to fill it out and return it within 2 weeks (n = 100). The
second group consisted of female master students study-
ing at the Medical School of the University Groningen
(n = 100). On the basis of a difference of 20%, alpha
0.05 and 80% power, n = 100 was concluded to be a
sufficient sample size.
The study was approved by the Medical Ethic Com-
mittee of the University Medical Centre Groningen.
The questionnaire consisted of four parts. Each part
contained a ‘textbox’ in which the propositions listed
further down were briefly clarified. The first part dealt
with the present condition around the testing for Down
syndrome. In the textbox the correlation between the age
of the pregnant woman and the chance of having Down
syndrome was mentioned, followed by a description of
the available diagnostic possibilities. The main advan-
tages and disadvantages of the available tests on the
basis of concrete risk and detection percentages were
also mentioned. Subsequently a number of statements
about this were presented.
The second part dealt with the situation in the future.
In the textbox is explained that DNA of the child is
present in the blood of the mother and that in future
it is to be expected that by a blood sample taken from
her at an early stage of her pregnancy the diagnosis of
Down syndrome can be made with a high certainty. In
that case amniocentesis and chorionic villus sampling
would become unnecessary. Subsequently we included
a number of statements about this diagnostic option.
In the third part the subject was extended to the appli-
cation of NIPD for gender determination. Statements
were presented on the basis of three situations. The first
situation related to gender determination in the case of
congenital genetic disorders, in this case the disease of
Duchenne. Apart from describing the development of the
disease, we also mentioned that it only occurs in males,
explaining that further invasive procedures to determine
the presence of this affliction would only be necessary
in the case of a male fetus. A second situation concerned
gender determination for genetic disorders manifesting
themselves later in life. We indicated prevalence and
risk percentage in the case of genetic breast cancer and
that further invasive procedures would only be neces-
sary in the case of a female fetus, since male carriers
rarely develop breast cancer. In the third situation we
focused on ‘gender determination for nonmedical rea-
sons’. It was stated that parents may simply be curious
as to the gender of their child, but parents may also have
a strong preference for one gender over the other. The
need for family balancing and the risk of sex selection
were also mentioned.
The last part of the questionnaire concerned the
application of NIPD as a screening tool for congenital
disorders in a wider sense. Prior to the statements
the following information was included in the textbox:
‘The majority of children are born healthy, but a small
percentage (2–3%) is born with a congenital disorder. At
the moment, prenatal diagnosis is restricted to pregnant
women with a greater risk of a child suffering from a
congenital disorder. In the near future NIPD will make
it possible for all pregnant women to be noninvasively
screened early in their pregnancy’. We also mentioned
that the number of genetic disorders detectable via
NIPD will continue to rise. Finally respondents were
confronted with the fact that due to modern diagnostics a
pregnant woman’s choice as to whether or not terminate
her pregnancy will be made at an ever earlier stage
in pregnancy. This was formulated as follows: ‘In a
number of cases pregnancy would have resulted in
an early miscarriage. Early miscarriages are relatively
frequent: at least one in ten pregnancies ends in an early
miscarriage. Its cause is usually a defect in the fetus.
This means that without early detection a considerable
number of pregnancies would have ended in a natural
way and the choice as to whether or not to terminate
pregnancy would not have presented itself’.
Questionnaires were handed out until 100 fully com-
pleted questionnaires had been returned by each group.
The questionnaire was based on a questionnaire used
in a previous study (Weinans et al., 2000). Data were
analyzed by the Statistical Package for Social Sciences
(SPSS/Windows). Five-point Likert scales were limited
to three categories to avoid small cells. The responses
to the propositions of the two groups were analyzed
to determine if there were any significant differences
between them. The difference in age and education was
also evaluated. Statistical testing of differences between
the groups was done using Chi-square distribution.
RESULTS
General
Some background characteristics of the respondents are
shown in Table 1. As expected the pregnant women
are significantly older than the female medical students
(average age 32.0 vs 21.6).
Testing for Down syndrome: now and in
the future
The results in Table 2 show that a majority of the
respondents are critical of offering invasive prenatal tests
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on a general basis. Only 11% of the students agree with
the statement that chorionic villus and amniocentesis
should be supplied to all pregnant women, regardless
of age. Forty-five percent of the pregnant women agree
(p < 0.05). A general offer of noninvasive screening
tests is given a more positive rating by both groups.
Three quarters of the pregnant women agree with the
statement that the blood test in combination with nuchal
translucency screening should be offered to all pregnant
women versus 63% of the students.
The attitudes of the respondents differ toward a gen-
eral offer of NIPD. Eighty-one percent of the preg-
nant women support the statement that NIPD should be
offered to all pregnant women in order to detect Down
syndrome in an early stage of pregnancy. Forty-nine per-
cent of the students agree to this statement (p < 0.05).
Both groups largely support the statement that NIPD
is an important asset in prenatal screening for Down
syndrome.
NIPD within the framework of gender
determination
Table 3 shows to what extent the respondents support
offering NIPD within the framework of gender deter-
mination. Pregnant women as well as students show
massive support for the statement that NIPD is an impor-
tant asset in prenatal screening for gender-determined
congenital disorders. The respondents are less positive
about NIPD for congenital disorders occurring later in
life. Forty-eight percent of the pregnant women support
the proposition that NIPD is an important asset within
prenatal screening for congenital breast cancer. Only
17% of the students support this proposition (p < 0.05).
The statement that NIPD may only be used for gender
determination if there are medical reasons to do so and
not for family balancing is supported by a majority of
respondents in both groups.
NIPD: wider use
The respondents’ attitudes toward the use of NIPD as
part of testing fetal abnormalities are listed in Table 4.
The statement that DNA screening in an early stage of
pregnancy may be considered a significant asset, because
it enables every pregnant woman to bear a healthy
child, is strongly rejected by the pregnant women as
well as the students. On the other hand, the majority
of both groups of respondents agree with the statement
that NIPD is a significant asset in the present prenatal
care. Forty-one percent of the pregnant women and
37% of the students agree that the advantage of timely
detection counterbalances the disadvantage of a possibly
unnecessary choice to terminate a pregnancy. This in
spite of the fact that a number of the pregnancies with
an affected fetus would have ended in a miscarriage
anyway.







I think that amniocentesis and chorionic villus sampling should be offered to all pregnant women regardless of their age
Agree 45 11
Disagree 44 83
Neither agree nor disagree 11 6
I think that screening tests (blood test in combination with nuchal translucency screening) should be offered to all pregnant
women regardless of their age
Agree 74 63
Disagree 18 27
Neither agree nor disagree 8 10




Neither agree nor disagree 5 15
I consider NIPD an important asset in screening for Down syndrome
Agree 92 89
Disagree 2 4
Neither agree nor disagree 6 7
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I consider NIPD in an early stage of pregnancy an important asset in prenatal diagnosis of gender-determined congenital disorders
Agree 90 85
Disagree 2 4
Neither agree nor disagree 8 11
NIPD is an important asset within prenatal screening for congenital breast cancer
Agree 48 17
Disagree 26 53
Neither agree nor disagree 26 30
In my opinion NIPD should only be used for gender determination for medical reasons, not for family balancing
Agree 84 92
Disagree 9 5
Neither agree nor disagree 7 3







I consider NIPD in an early stage of pregnancy a great asset, because it enables every pregnant woman to bear a healthy child
Agree 30 13
Disagree 38 66
Neither agree nor disagree 32 21
NIPD is an important asset in present prenatal care
Agree 82 79
Disagree 5 7
Neither agree nor disagree 13 14




Neither agree nor disagree 34 27
DISCUSSION
Modern biotechnology offers more and more possibili-
ties for an early detection of abnormalities. Compared
with the present methods for the detection of Down syn-
drome NIPD has advantages: no risk for miscarriage and
a high sensitivity. When a reliable test becomes avail-
able, it will be possible to routinely screen all pregnant
women. This is progress, but it also means that there
will be changes in the choices that are made in screening
for Down syndrome. In the case of invasive testing, the
choice is far-reaching and not without risk and therefore
made consciously. ‘Our survey shows that a minority of
the women think that invasive tests should be offered
to all pregnant women, regardless of their age’. This
corresponds with the present restrained policy in the
Netherlands of availability of invasive testing only for
women who are considered to be at increased risk.
The risk-assessment tests are noninvasive and there
is no chance of miscarriage, thus facilitating the choice.
On the downside there remains the fact that these tests
do not result in a full accuracy. NIPD is not only simple
and risk-free to carry out but it also supplies direct
certainty in an early stage of pregnancy. In spite of these
advantages our respondents do not agree about making
this test generally available: a majority of the pregnant
women support a general availability of NIPD, whereas
the students are far more reluctant. In previous research
it was also shown that female medical students are less
positive about offering testing (Kooij et al., 2005). An
explanation might be that they are more aware of the
negative effects. Both groups agree, however, that NIPD
is an important asset in prenatal screening for Down
syndrome. Therefore we may expect to see a substantial
rise in participation in prenatal screening.
NIPD can also be used for the diagnosis of many other
congenital disorders. A general availability of NIPD
will therefore have far-reaching consequences and the
situation in the field of prenatal diagnosis will change
drastically. Our survey shows that women support the
use of NIPD for gender determination in connection with
gender-related genetic disorders. In the case of genetic
disorders manifesting themselves later in life attitudes
are more critical. An explanation for this might be that
people have to deal with choices and responsibilities
that they have no longer a clear view of. Gender
determination for nonmedical reasons is clearly rejected.
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Every pregnancy carries a chance of a child with a
congenital defect. NIPD makes early detection possible.
It is estimated that at least one in ten and possibly
even 25–30 or 40% of pregnancies end in an early
miscarriage; usually as a result of an abnormality in
the fetus. These defects are detected earlier and earlier
and as a result there is a surge in pathology, which
now is partly filtered out by evolution. Early detection
also means that in an early stage of their pregnancy
women have to decide whether or not to terminate it.
In a number of cases a choice would not have been
necessary, because the pregnancy would have resulted
in a miscarriage anyway. From our survey it is clear
that for more than one-third of the respondents this is
not seem to be as a reason not to subject to the tests
(Table 4).
A general availability of NIPD may result in fewer
births of children with a congenital defect. When directly
confronted with this, the respondents became hesitant.
Only a small number of respondents consider it an
asset that NIPD enables the birth of a healthy child.
This shows that people do not always seem to realize
all consequences of screening. No doubt NIPD will
be the future and paves the way for screening on a
large scale. Our survey shows that women feel positive
about these new possibilities but find it hard to fully
realize the consequences and new choices women will
be confronted with. In addition to the technical aspects,
it is now time to evaluate its psychosocial aspect
and end-users’ acceptance. This study belongs to this
category and can be considered as a first step to a wider
discussion.
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